论文部分内容阅读
目的：探讨赖诺普利对高血压患者血小板活化功能、血脂、胰岛素抵抗（ＩＲ）的干预作用。方法：对１１７例高血压患者用赖诺普利治疗４ 周，治疗前后观察血中血小板颗粒膜蛋白（ＧＭＰ－１４０）、空腹血糖（ＦＢＧ）、空腹胰岛素（ＦＩＮＳ）、胆固醇（ＣＨ）、高密度脂蛋白（ＨＤＬ）、甘油三酯（ＴＧ），计算胰岛素敏感指数（ＩＳＩ），并以３２ 例正常人对照。结果：赖诺普利有效降低高血压患者血压（ Ｐ＜ ０．０５）。并且显著降低ＦＢＧ、ＦＩＮＳ、ＴＧ、ＧＭＰ－１４０，升高ＩＳＩ（Ｐ＜０．０５）。ＣＨ、ＨＤＬ无显著变化（ Ｐ＞ ０．０５）。结论：高血压病存在ＩＲ、血脂代谢异常，血小板粘附力增强。赖诺普利在有效降压同时，可以纠正基础代谢紊乱
Objective: To investigate the effects of lisinopril on platelet activation, blood lipid and insulin resistance (IR) in patients with essential hypertension. Methods: 117 patients with hypertension were treated with lisinopril for 4 weeks. The levels of GMP-140, fasting blood glucose (FBG), fasting insulin (FINS), cholesterol (CH) Density lipoprotein (HDL), triglyceride (TG), insulin sensitivity index (ISI) were calculated and 32 normal controls were used. Results: Lisinopril effectively reduced blood pressure in hypertensive patients (P <0.05). And significantly lower FBG, FINS, TG, GMP-140, increased ISI (P <0.05). CH, HDL no significant change (P> 0.05). Conclusion: Hypertension exists IR, dyslipidemia and platelet adhesion enhancement. Lisinopril in the effective antihypertensive at the same time, you can correct the basic metabolic disorders